Can a smartphone app improve cancer care? new study aims to find out.
NCT ID NCT06860425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether cancer patients will regularly use a mobile app called RestoreMe to help with diet, nutrition, and activity during their treatment. About 50 patients with various cancers (like breast, lung, or prostate) who are getting radiation therapy will be asked to use the app. The main goal is to see if patients find the app useful and satisfying, not to directly treat the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2023
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of invasive malignancy of the brain, head and neck region, lung, breast (DCIS and invasive disease allowed), prostate, gastrointestinal system or gynecological region * Planned to receive, or have received, radiation therapy treatment with curative intent * Note: Patients undergoing systemic therapy are eligible * Note: Any dose/fractionation of curative-intent radiation therapy is eligible * Patients must have a smartphone or other device with the ability to receive text messages, download and use mobile applications * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to read and write in English * Provide written informed consent to participate in the study o NOTE: Patients enrolled on another clinical trial are eligible Exclusion Criteria: * Metastatic cancer * Undergoing treatment with palliative intent * Poorly controlled diabetes (defined as fasting glucose level \> 200 mg/dL despite attempts to improve glucose control by fasting duration and adjustment of medications) * Uncontrolled hypertension * Any medical condition requiring fluid restriction or nutrient restrictions
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Montefiore Einstein Comprehensive Cancer Center
RECRUITINGThe Bronx, New York, 10461, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which PICC insertion method causes fewest complications?
- Could a 7-Minute app match a gym session for fitness and sleep?
- Digital exercise program aims to boost recovery for breast cancer survivors
- Decoding Immunotherapy's liver side effect to keep cancer treatment on track
- New therapy aims to ease the heavy burden on cancer caregivers
- Can a phone app teach nurses to make tough ethical calls?